Dr. Johnson on the Limitations of Biomarkers in Melanoma
Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.
Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Neal Shore, MD, FACS, discusses the importance of a multidisciplinary team in light of recent developments in urologic oncology.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
18F-DCFPyL PSMA-PET imaging plus multi-parametric MRI improved the detection of clinically significant prostate cancer in low- and high-risk men on active surveillance.
The investigational therapy IGNK001 has received orphan drug designation from the FDA for patients with acute myeloid leukemia.
Mark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.
Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.
Enzalutamide alone and with leuprolide led to greater rates of undetectable PSA levels vs leuprolide alone in castration-sensitive prostate cancer.
Erin Frances Cobain, MD, highlights the current role of endocrine therapy and CDK4/6 inhibitors in HR-positive, HER2-negative metastatic breast cancer.